Exelixis Inc Variable Lease, Cost
Exelixis Inc (EXEL) reported Variable Lease, Cost of $8.02 million for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-10
- Exelixis Inc variable lease, cost for the quarter ending 2020-01-03 was $370.00K, a 25.42% increase year-over-year.
- Exelixis Inc variable lease, cost for the quarter ending 2019-09-27 was $274.00K, a 24.52% decline year-over-year.
- Exelixis Inc variable lease, cost for the quarter ending 2019-06-28 was $131.00K, a 75.33% decline year-over-year.
- Exelixis Inc variable lease, cost for the quarter ending 2018-12-28 was $295.00K, a 80.48% decline year-over-year.
- Exelixis Inc variable lease, cost for fiscal 2026 was $8.02M, a 13.58% decline from fiscal 2025.
- Exelixis Inc variable lease, cost for fiscal 2025 was $9.28M, a 31.24% increase from fiscal 2023.
- Exelixis Inc variable lease, cost for fiscal 2023 was $7.07M, a 128.15% increase from fiscal 2022.
- Exelixis Inc variable lease, cost for fiscal 2022 was $3.10M, a 15.38% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-01-02 | $8.02M 10-K · filed 2026-02-10 | |||
| 2025-01-03 | $9.28M 10-K · filed 2026-02-10 | |||
| 2023-12-29 | $7.07M 10-K · filed 2026-02-10 | |||
| 2022-12-30 | $3.10M 10-K · filed 2025-02-11 | |||
| 2021-12-31 | $2.69M 10-K · filed 2024-02-06 | |||
| 2021-01-01 | $2.83M 10-K · filed 2023-02-07 | |||
| 2020-01-03 | $370.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $644.00K derived: sum of 2 quarters · filed 2022-02-18 | $775.00K derived: sum of 3 quarters · filed 2022-02-18 | $1.02M 10-K · filed 2022-02-18 |
| 2019-09-27 | $274.00K 10-Q · filed 2019-10-30 | $405.00K derived: sum of 2 quarters · filed 2019-10-30 | $654.00K 10-Q · filed 2019-10-30 | |
| 2019-06-28 | $131.00K 10-Q · filed 2019-07-31 | $380.00K 10-Q · filed 2019-07-31 | ||
| 2018-12-28 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $658.00K derived: sum of 2 quarters · filed 2020-02-25 | $1.19M derived: sum of 3 quarters · filed 2020-02-25 | $1.66M 10-K · filed 2021-02-11 |
| 2018-09-28 | $363.00K 10-Q · filed 2019-10-30 | $894.00K derived: sum of 2 quarters · filed 2019-10-30 | $1.37M 10-Q · filed 2019-10-30 | |
| 2018-06-29 | $531.00K 10-Q · filed 2019-07-31 | $1.00M 10-Q · filed 2019-07-31 | ||
| 2017-12-29 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $1.74M derived: sum of 2 quarters · filed 2019-02-22 | $2.22M 10-K · filed 2019-02-22 | |
| 2017-09-29 | $229.00K 10-Q · filed 2018-11-01 | $705.00K 10-Q · filed 2018-11-01 | ||
| 2016-12-30 | $1.06M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |